Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All colchicine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 65% Improvement Relative Risk Ventilation 60% ICU admission 71% Colchicine for COVID-19  Elshiwy et al.  META ANALYSIS c19early.org Favors colchicine Favors control

The Role of Colchicine in the Management of COVID-19: A Meta-analysis

Elshiwy et al., Research Square, doi:10.21203/rs.3.rs-3140344/v1
Dec 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Colchicine for COVID-19
5th treatment shown to reduce risk in September 2020
 
*, now known with p = 0.00000018 from 53 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19early.org
Systematic review and meta-analysis of 8 studies (4 RCTs) involving 16,488 COVID-19 patients showed significantly lower mortality and oxygen therapy needs with colchicine treatment compared to placebo or standard care.
10 meta analyses show significant improvements with colchicine for mortality Danjuma, Elshafei, Elshiwy, Golpour, Lien, Rai, Salah, Zein, oxygen therapy Elshiwy, hospitalization Kow, and severity Yasmin.
Currently there are 53 colchicine for COVID-19 studies, showing 29% lower mortality [19‑39%], 29% lower ventilation [-15‑56%], 31% lower ICU admission [4‑51%], 19% lower hospitalization [10‑27%], and 9% more cases [-8‑29%].
risk of death, 65.0% lower, RR 0.35, p = 0.01.
risk of mechanical ventilation, 60.0% lower, RR 0.40, p = 0.09.
risk of ICU admission, 71.0% lower, RR 0.29, p = 0.08.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Elshiwy et al., 12 Dec 2023, preprint, 5 authors. Contact: kholoudelshiwy@gmail.com.
This PaperColchicineAll
The Role of Colchicine in the Management of COVID-19: A Meta-analysis
Kholoud Elshiwy, Ghada Essam El-Din Amin, Mohamed Nazmy, Rasha Samir, Mohamed Farouk Allam
doi:10.21203/rs.3.rs-3140344/v1
Background: The Coronavirus disease 2019 pandemic has robustly affected the global healthcare and economic systems. The causative agent is coronavirus-2 (SARS-CoV-2). The clinical presentation of the disease ranges from a u-like illness to severe pneumonia and death. Till September 2022, the cumulative number of cases exceeded 600 million worldwide and deaths were more than 6 million. Colchicine is an alkaloid drug that is used in many autoin ammatory conditions e.g., gout, familial Mediterranean fever, and Behçet's syndrome. Objective: The aim of the current study was to assess the evidence of colchicine effectiveness in COVID-19 treatment. Patients and methods: A comprehensive review of the literature was done till May 2022 and yielded 814 articles after ranking the articles according to authors and year of publication. Only 8 clinical trials and cohort studies ful lling the inclusion criteria were included for further steps of data collection, analysis, and reporting. Results: The results showed that colchicine resulted in a signi cant reduction in the mortality rate among patients received colchicine in comparison with placebo or standard care (RR 0.35, 95%CI: 0.15-0.79). Colchicine resulted in a signi cant decrease in the need for O2 therapy in patients with COVID-19 (RR 0.07, 95%CI 0.02-0.27, P=0.000024). However, colchicine had no signi cant effect on the following outcomes among COVID-19 patients: the need for hospitalization, ICU admission, arti cial ventilation, and hospital discharge rate. Among the PCR con rmed COVID-19 patients, colchicine decreased the hospitalization rate (RR 0.75, 95%CI 0.57-0.99, P=0.042). However, colchicine had no effect on mortality and the need for mechanical ventilation among this subgroup. Conclusion: Colchicine caused a signi cant clinical improvement among COVID-19 patients as compared with the standard care or placebo, in terms of the need for O2, and mortality. This bene cial effect could play a role in the management of COVID-19 especially severe cases.
-Consent for publication: Not applicable -Availability of data and materials: Our study is a Systematic Review/Meta-analysis. The datasets analyzed during the current study are available in the published pooled study. Also, the datasets used and analyzed during the current study available from the corresponding author on reasonable request. -Competing interests: no competing interests -Funding: no funding Con icts of interest: None. -Authors' contributions: Kholoud Elshiwy: Field work supervision, analysis strategy and design, data management, data analysis and interpretation of results, decision making on content and paper write-up and revision of nal draft. Ghada Essam El-Din Amin: Field work supervision, analysis strategy and design, data management, data analysis and interpretation of results, decision making on content and paper write-up and revision of nal draft. Mohamed Nazmy: Field work supervision, analysis strategy and design, data management, data analysis and interpretation of results, decision making on content and paper write-up and revision of nal draft. Rasha Samir: Field work supervision, analysis strategy and design, data management, data analysis and interpretation of results, decision making on content and paper write-up and revision of nal draft. Mohamed Farouk Allam: Field work supervision, analysis strategy and design, data management, data analysis and interpretation of results, decision making on content and paper write-up and revision of nal draft...
References
Bhattacharyya, Panda, Gupta, Anti-Mitotic Activity of Colchicine and the Structural Basis for Its Interaction withTubulin, Med Res Rev
Bozkurt, Bicak, Sipahi, The effects of colchicine on the progression and regression of encapsulating peritoneal sclerosis, Experimental Encapsulating Peritoneal Sclerosis Peritoneal Dialysis International
Brunetti, Diawara, Tsai, Colchicine to weather the cytokine storm in hospitalized patients with COVID-19, Journal of Clinical Medicine
Cascella, Rajnik, Cuomo, Dulebohn, Evaluation and Treatment Coronavirus (COVID-19
Cronstein, Esserman, Sunkureddi, Mechanistic Aspects of In ammation and Clinical Management of In ammation in Acute Gouty Arthritis, J Clin Rheumatol
Deftereos, Giannopoulos, Vrachatis, Effect of Colchicine vs Standard Care on Cardiac and In ammatory Biomarkers and Clinical Outcomes in Patients Hospitalized with Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial, JAMA Network Open
Eikelboom, Jolly, Belley-Cote, Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial, The Lancet. Respiratory Medicine
Elshafei, El-Bardissy, Khalil, Colchicine use might be associated with lower mortality in COVID-19 patients: A meta-analysis, European Journal of Clinical Investigation
Group, Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, The Lancet Respiratory Medicine
Hageman, The coronavirus disease 2019 (COVID-19, Pediatric Annals
Han, Lin, Jin, You, Coronavirus 2019-nCoV: A brief perspective from the front line, Journal of Infection
Hariyanto, Halim, Jodhinata, Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis, Clinical and Experimental Pharmacology and Physiology
Hoffmann, Kleine-Weber, Schroeder, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor, Cell
Jiang, Du, Shi, An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies, Emerging microbes & infections
Klok, Kruip, Van Der Meer, Incidence of thrombotic complications in critically ill ICU patients with COVID-19, Thrombosis Research
Korkmaz, Erturan, Nazirogľu, Colchicine modulates oxidative stress in serum and neutrophil of patients with Behçet disease through regulation of Ca 2+ release and antioxidant system, Journal of Membrane Biology
Kow, Lee, Ramachandram, The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID-19: A meta-analysis of randomized trials, Immunity, In ammation and Disease
Lho, Do, Heo, Molecular Sciences Effects of TGF-β1 Receptor Inhibitor GW788388 on the Epithelial to Mesenchymal Transition of Peritoneal Mesothelial Cells, doi:10.3390/ijms22094739
Lopes, Bonjorno, Giannini, Bene cial effects of colchicine for moderate to severe COVID-19: A randomised, double-blinded, placebo-controlled clinical trial, RMD Open
Lu, Zhao, Li, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, The Lancet
Mareev, Orlova, Plisyk, Proactive anti-in ammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The rst results of the COLORIT study, Kardiologiya
Mehta, Patel, Chavda, E cacy and safety of colchicine in COVID-19: A meta-analysis of randomised controlled trials, RMD Open
Sandhu, Tieng, Chilimuri, Franchin, A case control study to evaluate the impact of colchicine on patients admitted to the hospital with moderate to severe covid-19 infection, Canadian Journal of Infectious Diseases and Medical Microbiology
Sanghavi, Bansal, Kaur, Impact of colchicine on mortality and morbidity in COVID-19: a systematic review, Annals of Medicine
Scarsi, Piantoni, Colombo, Association between treatment with colchicine and improved survival in a singlecentre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome, Annals of the Rheumatic Diseases
Schlesinger, Firestein, Brunetti, Colchicine in COVID-19: an Old Drug, New Use, Current Pharmacology Reports
Stokes, Zambrano, Anderson, Coronavirus Disease 2019 Case Surveillance -United States, MMWR. Morbidity and Mortality Weekly Report
Tardif, Bouabdallaoui, L'allier, Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial, The Lancet Respiratory Medicine
Toro-Huamanchumo, Benites-Meza, Mamani-García, E cacy of Colchicine in the Treatment of COVID-19 Patients: A Systematic Review and Meta-Analysis, Journal of Clinical Medicine
Van Doremalen, Bushmaker, Morris, Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1, New England Journal of Medicine
Weiss, Navas-Martin, Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus, Microbiology and Molecular Biology Reviews
Wu, Leung, Leung, Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study, The Lancet
Wu, Mcgoogan, Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention, JAMA -Journal of the American Medical Association
Xu, Shi, Wang, Pathological ndings of COVID-19 associated with acute respiratory distress syndrome, The Lancet Respiratory Medicine
Zein, Raffaello, Effect of colchicine on mortality in patients with COVID-19 -A systematic review and meta-analysis, Diabetes and Metabolic Syndrome: Clinical Research and Reviews
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit